会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 9. 发明公开
    • SAMHD1 MODULATION FOR TREATING RESISTANCE TO CANCER THERAPY
    • SAMHD1-MODULATION ZUR BEHANDLUNG VON RESISTENZ GEGEN KREBSTHERAPIE
    • EP3163302A1
    • 2017-05-03
    • EP15192494
    • 2015-11-02
    • JOHANN WOLFGANG GOETHE-UNIVERSITÄT FRANKFURT AM MAINRHEINISCHE FRIEDRICH-WILHELMS-UNIVERSITÄT BONN
    • KEPPLER OLIVER TILLCINATL JINDRICHSCHNEIDER CONSTANZEBALDAUF HANNA-MARISCHWARZ SARAH-MARIESERVE HUBERTOELLERICH THOMASGEISSLINGER GERDHORNUNG VEIT
    • G01N33/574
    • G01N33/57426C12N2710/24132G01N2800/52
    • The present invention pertains to novel treatments for cancer diseases. Treatment of cancers with nucleoside analogs (NA), which specifically inhibit rapidly dividing cells, may face preexisting NA resistance or development of resistant cancer cells resulting in poor clinical prognosis. Treatment of cancers with oncolytic herpes simplex viruses (HSV) may face preexisting resistance or development of resistant cancer cells resulting in poor clinical prognosis. The invention overcomes chemotherapy resistance or resistance to oncolytic HSV by providing methods for detecting the resistance in a cancer disease based on the expression of SAM domain and HD domain-containing protein 1 (SAMHD1) in cancer cells. Furthermore provided are treatment options addressing the chemotherapy resistance such as a combination of a SAMHD1 inhibitor with a NA. Moreover, provided are treatment options addressing the resistance to oncolytic HSV such as a combination of a SAMHD1 inhibitor or depletion of SAMHD1 with an oncolytic HSV. The invention provides new medicines and companion diagnostics supporting clinical treatment decisions.
    • 本发明涉及癌症疾病的新型治疗。 用特异性抑制快速分裂细胞的核苷类似物(NA)治疗癌症可能面临预先存在的NA耐药或发展抗性癌细胞,导致临床预后不良。 用溶瘤性单纯疱疹病毒(HSV)治疗癌症可能面临预先存在的抗性或发展抗性癌细胞,导致临床预后不良。 本发明通过提供基于SAM结构域和含HD结构域的蛋白质1(SAMHD1)在癌细胞中的表达来检测癌症疾病中的抗性的方法来克服化疗耐受性或对溶瘤性HSV的抗性。 此外提供了解决化疗耐药性的治疗选择,例如SAMHD1抑制剂与NA的组合。 此外,提供了治疗选择,其解决对溶瘤HSV的抗性,例如SAMHD1抑制剂或SAMHD1消耗与溶瘤HSV的组合。 本发明提供支持临床治疗决定的新药物和伴侣诊断。